Drug firm Cadila Healthcare on Tuesday reported a 52 per cent rise in its consolidated net profit to Rs 281.91 crore for the third quarter ended December 31, 2014 on back of robust sales.
The company had posted a net profit after taxes, minority interest and share of profit/loss of associates of Rs 185.97 crore for the corresponding period of the previous fiscal.
Consolidated total income from operations of the company also rose to Rs 2,189.46 crore for the quarter under consideration as against Rs 1,871.69 crore for the same period year ago, Cadila Healthcare said in a filing to BSE.
During the quarter, the company's business in the US registered a growth of 42 per cent while emerging markets business grew by 23 per cent, Cadila Healthcare said.
The company had filed 5 additional abbreviated new drug applications (ANDAs) during the third quarter with the US Food and Drug Administration (USFDA), taking the cumulative ANDA filings to 255, it added.
"During the quarter, the company launched Exemptia, the world's first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis," Cadila Healthcare said.
The group's R&D pipeline which comprises 25 biologics (including novel biologics) is being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke, it added.
Shares of Cadila Healthcare were trading at Rs 1,521.25 per scrip in the afternoon trade on BSE, up 3.09 per cent from its previous close.